Literature DB >> 9448109

Potentiation of pirarubicin activity in multidrug resistant cells by rifampicin.

S Furusawa1, S Nakano, J Wu, K Sasaki, M Takayanagi, Y Takayanagi.   

Abstract

The effect of the anti-tuberculosis drug rifampicin on pirarubicin activity was investigated in multidrug-resistant cells overexpressing P-glycoprotein. Rifampicin increased the sensitivity of pirarubicin to anthracycline-resistant mouse leukemic P388 cells and significantly enhanced the cytotoxicity and intracellular accumulation of pirarubicin in resistant cells, but had no effect in parent cells. By contrast, two other rifamycins, rifamycin B and SV, had no effect on pirarubicin accumulation in resistant cells. Rifampicin also enhanced pirarubicin-induced apoptosis and G2/M blockade on the cell cycle in resistant cells. These results show that rifampicin enhances the cytotoxic action of pirarubicin in resistant cells, at least partly via the inhibition of cellular pirarubicin efflux.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9448109     DOI: 10.1248/bpb.20.1303

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  1 in total

1.  Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.

Authors:  Akshanth R Polepally; Juki W Ng; Ahmed Hamed Salem; Matthew B Dufek; Apurvasena Parikh; David C Carter; Kent Kamradt; Nael M Mostafa; Mohamad Shebley
Journal:  J Clin Pharmacol       Date:  2020-07-07       Impact factor: 3.126

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.